The Efficacy and Safety of Luspatercept in Improving Early Anemia After HSCT

Starting soon · Phase 2

Conditions studied: HSCT

In brief

This study aims to evaluate whether luspatercept can improve the efficacy and safety of anemia treatment in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation.

Key facts

Study ID

NCT07450313

Run by

Institute of Hematology & Blood Diseases Hospital, China

People needed

20

Starts

2026-03-14

Expected to finish

2027-06-14

Last updated by the study team

2026-03-04

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 1. Diagnosis of malignant hematological tumors and undergoing allogeneic hematopoietic stem cell transplantation.
• 2. Expected survival after transplantation exceeds 1 month.
• 3. Age 18-60 years.
• 4. Hemoglobin ≤60 g/L on day 0 after transplantation.
• 5. Eastern Cooperative Oncology Group (ECOG) score 0-2.
• 6. Able to independently sign the informed consent form.
• 7. The informed consent form must be signed before the start of the study procedures. For individuals aged 18 years and above, the informed consent form should be signed by the patient themselves or their immediate family members. Considering the patient's condition, if signing by the patient themselves is not conducive to treatment, the legal guardian or immediate family member should sign the informed consent form.

You may not qualify if…

• 1. Uncontrolled infection at the time of enrollment, or requiring mechanical ventilation or hemodynamic instability;
• 2. Severe organic damage: hepatic or renal impairment;
• 3. Occurrence of any of the following within 6 months prior to the study: myocardial infarction, severe/unstable angina pectoris, congestive heart failure, or cerebrovascular accident, including transient ischemic attack;
• 4. Presence of psychiatric disorders or other conditions that may compromise compliance with study treatment and monitoring requirements. Failure to sign the informed consent form;
• 5. Inability or unwillingness to sign the consent form;
• 6. Participation in other transplant-related clinical studies;
• 7. Other circumstances deemed by the investigator as potentially affecting the study or ethics, including drug allergies, patient non-compliance with study procedures, or involvement of the research center staff and their immediate relatives.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.